CStone’s CS2009 Delivers Strong NSCLC and CRC Results at ASCO 2026
SUZHOU, China, June 1, 2026 CStone Pharmaceuticals announced updated clinical data for CS2009, its investigational PD-1/VEGF/CTLA-4 trispecific antibody, at...
PD-1
Advertisement
Innovent IBI363 Shows Strong Survival in NSCLC
SAN FRANCISCO and SUZHOU, China, May 21, 2026 Innovent Biologics, Inc. announced updated long-term clinical data from the Phase...
Phio Pharmaceuticals Showcases PH-762 Skin Cancer Trial Progress
KING OF PRUSSIA, Pa., May 12, 2026 Phio Pharmaceuticals announced that company leadership will participate in a virtual fireside...
Kelun-Biotech Gains China IND Clearance for SKB118
CHENGDU, China, May 12, 2026 Kelun-Biotech announced that China’s Center for Drug Evaluation (CDE) under the National Medical Products...
Adagene & Incyte Drive New MSS CRC Immunotherapy Study
San Diego, USA & Suzhou, China, April 2, 2026 Breakthrough Collaboration in Immuno-Oncology In a significant step forward for...
Advertisements
Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762
Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...
Phio Pharmaceuticals Strengthens Governance with New Lead Director
King of Prussia, Pennsylvania – October 31, 2025 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...
Advertisement
